moxifloxacin (Avelox)

Subscribe to Selected New Research on moxifloxacin

508 relevant articles (78 outcomes, 125 trials/studies) found for this Drug

Also Known As:

Avelox; 1-cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; Actira; Avalox; BAY 12-8039; BAY 128039; BAY-12-8039; BAY-128039; Bayer brand of moxifloxacin hydrochloride; Esteve brand of moxifloxacin hydrochloride; Izilox; Octegra; Proflox; Vita brand of moxifloxacin hydrochloride; moxifloxacin hydrochloride

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Aza Compounds: 3

moxifloxacin: 508

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Quinolines: 58

moxifloxacin: 508

Experts

1.	Tyagi, Sandeep: 7 articles (04/2008 - 06/2002)
2.	Landen, H: 7 articles (09/2007 - 03/2001)
3.	Choudhri, Shurjeel: 6 articles (05/2008 - 11/2004)
4.	Grosset, Jacques H: 6 articles (04/2008 - 02/2004)
5.	Bishai, William R: 6 articles (12/2007 - 02/2004)
6.	Haverstock, D: 6 articles (11/2005 - 01/2000)
7.	Church, D: 6 articles (10/2004 - 01/2000)
8.	Mah, Francis S: 5 articles (02/2008 - 09/2003)
9.	Stauch, K: 5 articles (01/2006 - 01/2004)
10.	Kubin, R: 5 articles (01/2003 - 03/2001)

Related Diseases

1.	Infection 03/01/2004 - "Moxifloxacin exhibited good to excellent antimicrobial activity against most aerobic (90.8%) and anaerobic (97.1%) microorganisms, suggesting that it may be effective for the treatment of polymicrobial surgical infections." 10/01/2005 - "How effective is moxifloxacin for the first-line treatment of patients with Helicobacter pylori infection?" 06/01/2004 - "Moxifloxacin, a new quinolone, is effective in vitro against several anaerobic bacteria including Bacteroides fragilis, but its in vivo activity against anaerobic infections is not known" 08/01/2003 - "Therapeutic efficacy of moxifloxacin in a murine model of severe systemic mixed infection with Escherichia coli and Bacteroides fragilis." 04/01/1998 - "These results suggested that BAY 12-8039 would be a promising agent for the eradication of respiratory tract pathogens and that clinical trials assessing its efficacy for the management of infections caused by these organisms are warranted." Get all the results and reference details, order at left...
2.	Pneumonia (Pneumonitis) 05/15/2008 - "Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial." 05/01/2005 - "Our objective was to study to what extent MV could influence the efficacy of moxifloxacin in a rabbit model of pneumonia" 07/01/2000 - "Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae." 08/01/2006 - "In cases of failure of empirical preclinical antibiotic treatment for community-acquired pneumonia, subsequent intrahospital treatment with moxifloxacin is more successful than standard therapy in our study reflecting a "real life scenario"." 12/01/2005 - "In clinical trials with patients receiving 400 mg moxifloxacin once daily for the treatment of community-acquired pneumonia (CAP) success rate was approximately 93.5%" Get all the results and reference details, order at left...
3.	Chronic Bronchitis 01/01/2007 - "Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis]" 09/01/2001 - "The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience." 11/01/2007 - "The aim of this study was to assess whether moxifloxacin is able to inhibit the synthesis of and to disrupt biofilms produced in vitro by bacterial pathogens involved in acute bacterial exacerbations of chronic bronchitis" 04/01/2006 - "BACKGROUND: The MOSAIC study compared moxifloxacin with three standard antibiotic regimens in patients with Anthonisen type 1 acute exacerbations of chronic bronchitis (AECB)" 03/01/2004 - "STUDY OBJECTIVES: To compare the effectiveness of oral moxifloxacin with standard antibiotic therapy in acute exacerbation of chronic bronchitis (AECB)" Get all the results and reference details, order at left...
4.	Sinusitis 01/01/2004 - "CONCLUSIONS: Moxifloxacin is a very effective and safe treatment for patients with acute sinusitis in general practice and is highly regarded by both physicians and patients because of rapid symptom improvement and good tolerability." 04/01/2000 - "Three comparative, prospective, randomized, double-blind studies in the treatment of community acquired sinusitis, AECB and CAP demonstrated equal or higher efficacy of moxifloxacin in comparison to standard antibiotic therapies." 01/01/2004 - "Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice : results of a post-marketing surveillance study." 05/01/2002 - "A pharmacokinetic study was carried out to determine moxifloxacin concentrations in sinus tissue, after oral moxifloxacin 400 mg once daily for 5 days to patients with chronic sinusitis, undergoing elective sinus surgery" 01/01/2006 - "Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis." Get all the results and reference details, order at left...
5.	Respiratory Tract Infections (Respiratory Tract Infection) 12/01/1999 - "12 mg/L) and indicate that moxifloxacin should be effective in the treatment of community-acquired, lower respiratory tract infections." 05/01/2004 - "CONCLUSIONS: Once-daily oral moxifloxacin 400 mg was shown to be safe and effective in this trial for the treatment of respiratory tract infections of suspected bacterial origin in the clinical practice setting." 03/01/2005 - "Efficacy of moxifloxacin in the treatment of respiratory tract infections: the Croatian post-marketing study]" 12/01/2003 - "In the present study, we examined the lung tissue diffusion of moxifloxacin at a dose of 400 mg administered intravenously or orally once-daily, and the results were correlated to microbiological data to estimate the clinical efficacy of moxifloxacin in lower community-acquired respiratory infections" 07/01/2008 - "METHOD: To perform a systematic review of publications on the clinical efficacy of moxifloxacin in respiratory infections" Get all the results and reference details, order at left...
164 Diseases and 508 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	gatifloxacin (Zymar)
2.	Ciprofloxacin (Cipro)
3.	Ofloxacin (Levofloxacin)
4.	Amoxicillin (Wymox)
5.	Vancomycin
6.	Clavulanic Acid (Potassium Clavulanate)
7.	Clarithromycin (Biaxin)
8.	Azithromycin (Zithromax)
9.	Anti-Bacterial Agents (Antibiotics)
10.	Quinolones
176 Drugs and Important Bio-Agents and 304 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Chemoprevention
3.	Intraocular Lens Implantation
4.	Laparoscopic Cholecystectomy
5.	Tonsillectomy
19 Therapies and Procedures and 23 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>